{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:24:53Z","timestamp":1778930693698,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ijrobp.2024.01.008","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T10:47:50Z","timestamp":1705056470000},"page":"1497-1506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial"],"prefix":"10.1016","volume":"118","author":[{"given":"Sarah","family":"Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linden","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella Mae","family":"Cruz-Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanah","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Berrang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quinn","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Carolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siavash","family":"Atrchian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ante","family":"Mestrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Valev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilo","family":"Lefresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Tyldesley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob A.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.01.008_bib0001","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABRCOMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0002","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0004","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0005","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ejso.2015.05.020","article-title":"Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0006","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.21.01032","article-title":"Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): A phase II or III randomized controlled trial","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0007","first-page":"1558","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A Prospective, randomized, multicenter phase II trial","volume":"37","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0008","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation versus stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0009","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: A single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0011","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0012","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: Primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0013","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5","volume":"18","author":"Olson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-free survival and local control after SABR for up to 5 oligometastases: An analysis from the population-based phase 2 SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0017","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0018","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0019","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: A propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0020","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/sim.9519","article-title":"Bootstrap versus asymptotic variance estimation when using propensity score weighting with continuous and binary outcomes","volume":"41","author":"Austin","year":"2022","journal-title":"Stat Med"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0023","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2022.08.026","article-title":"Validation of the prognostic utility of ESTRO\/EORTC oligometastatic disease classification: A secondary analysis from the population-based phase II SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: Introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0022","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0024","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): Final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0026","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0027","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0028","article-title":"Safety and tolerability of metastasis-directed radiation therapy in the era of evolving systemic, immune, and targeted therapies","volume":"7","author":"Guimond","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.008_bib0029","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2022.06.094","article-title":"Predictors of early polymetastatic relapse after SABR for up to 5 oligometastases: A secondary analysis of the phase II SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:11:57Z","timestamp":1759745517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0360301624000178"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.008","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}